Home > Insider Trading > Filing (0001209191-19-014933)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1439222	Agios Pharmaceuticals Inc	AGIO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1581956	Scott Biller	C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-02-27	1,766	$0.47	28,277	No	4	M	Direct
Common Stock	Acquisiton	2019-02-27	4,154	$9.05	32,431	No	4	M	Direct
Common Stock	Acquisiton	2019-02-27	3,080	$31.64	35,511	No	4	M	Direct
Common Stock	Disposition	2019-02-27	9,000	$65.00	26,511	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Disposition	2019-02-27	1,766	$0.00	1,766	$0.47
Common Stock	Stock option (right to buy)	Disposition	2019-02-27	4,154	$0.00	4,154	$9.05
Common Stock	Stock option (right to buy)	Disposition	2019-02-27	3,080	$0.00	3,080	$31.64

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2020-12-06	No	4	M	Direct
0	2023-04-30	No	4	M	Direct
11,782	2024-03-04	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	53,059	Indirect	See footnote

Footnotes

This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Shares held by a spousal lifetime access trust, of which the reporting person's wife is the trustee.
This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015.
This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.
This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.